

Manulife Global Fund - Global Multi-Asset Diversified Income Fund (the "ILP Sub-Fund")

This Fund Summary is for the above ILP Sub-Fund and should be read in conjunction with the Product Summary, Product Highlights Sheet and the underlying fund's Prospectus ("the Prospectus").

1. Structure of the ILP Sub-Fund

The ILP Sub-Fund is a feeder fund investing in the Manulife Global Fund - Global Multi-Asset Diversified Income Fund AA (SGD Hedged) MDIST (G) (the "Underlying Fund"). The Underlying Fund is a Sub-Fund of Manulife Global Fund, an umbrella structured, open-ended investment company (the "Company") which qualifies as a société d'investissement à capital variable under the law of 10 August 1915, as amended, of the Grand Duchy of Luxembourg. The Underlying Fund qualifies as a UCITS.

Please refer to sections "Important Information" and "The Sub-Funds" in the Prospectus for further information on the structure of the Underlying Fund.

Units of the ILP Sub-Fund ("Units") are not classified as Excluded Investment Products.

The ILP Sub-Fund is denominated in SGD.

Please refer to the latest available Prospectus, including any Singapore prospectus, supplement, product highlight sheet or fund-specific appendix, where applicable, for further information on the structure of the Underlying Fund. You may use the table of contents or index of the relevant document to locate the relevant disclosures.

2. Information on the ILP Sub-Fund Manager

The Company has designated Manulife Investment Management (Ireland) Limited ("MIM Ireland") to act as its Management Company (the "Management Company") pursuant to an amended and restated management company services agreement dated 1 October 2020 as novated by way of a novation agreement effective 1 July 2021 among Carne Global Fund Managers (Luxembourg) S.A., the Company and the Management Company (as may be amended from time to time) (the "Management Company Services Agreement").

MIM Ireland is domiciled in Ireland. MIM Ireland was incorporated on 4 October 2018 as a private company limited by shares, registered under Part 2 of the Companies Act 2014, under registration number 635225. MIM Ireland is regulated by the Central Bank of Ireland ("Central Bank") and was authorized by the Central Bank on 16 April 2019 as a UCITS management company pursuant to the European Communities (Undertakings for Collective Investment in Transferable Securities) Regulations 2011, as amended (the "UCITS Regulations") with authority to manage UCITS vehicles and oversee the activities of its delegates. On April 15, 2021, MIM Ireland was authorized by the Central Bank as an alternative investment fund manager pursuant to the European Union (Alternative Investment Fund Managers) Regulations 2013 (which shall be taken to include the provisions of the Central Bank's AIF Rulebook). Additionally, MIM Ireland is also approved to provide individual portfolio management services pursuant to Article 16(2)(a)(i) of the UCITS Regulations, as well as providing non-core services (to include investment advice, distribution and marketing) which have been passported into 30 jurisdictions, including Luxembourg. The Management Company has been managing collective investment schemes and/or discretionary funds since 2019.

The board of directors of the Management Company shall have plenary powers on behalf of the Management Company and shall cause and undertake all such actions and provisions which are necessary in pursuit of the Management Company's objective, particularly in relation to the management of the Company's assets, administration and distribution of Shares.

Pursuant to the Management Company Services Agreement, the Management Company is entrusted with the day-to-day management of the Company, with the responsibility to perform directly or by way of delegation operational functions relating to the investment management and the administration of the Company and the marketing and distribution of the Shares.

In agreement with the Company, the Management Company has decided to delegate several of its functions as is further described in this Singapore Prospectus.

The regulatory authority for the Management Company is the Central Bank of Ireland.

The Company may terminate the Management Company in the event of the insolvency of the Management Company. The appointment of a new management company is subject to regulatory approvals. The Company will notify the Shareholders of such an occurrence.

The Management Company has appointed Manulife Investment Management (US) LLC as the Investment Manager for the Underlying Fund (each an “Investment Manager” and collectively, the “Investment Managers”). The Co-Sub-Investment Managers of the Underlying Fund are Manulife Investment Management (Hong Kong) Limited and Manulife Investment Management (Europe) Limited. The Co-Sub-Investment Managers have agreed to provide sub-investment management services in respect of the Underlying Fund’s investments in Asian fixed income securities.

Past performance of the Management Company is not necessarily indicative of its future performance or the Underlying Fund.

The Investment Manager

Manulife Investment Management (US) LLC is incorporated and domiciled in the United States of America. Manulife Investment Management (US) LLC is regulated by the Securities and Exchange Commission in the United States and (as the successor to certain affiliated advisory firms) has managed collective investment schemes or discretionary funds since 1992.

The Management Company may appoint more than one Investment Manager (each such Investment Manager, a “Co-Investment Manager”) in respect of a Fund. Where the Management Company has done so, the Underlying Fund shall be jointly managed by the Co-Investment Managers as disclosed in the table under paragraph 3.3.1 above. Similarly, an Investment Manager may delegate its portfolio management functions to more than one Sub-Investment Manager (each such Sub-Investment Manager, a “Co-Sub-Investment Manager”) in respect of a Fund, as disclosed in the Prospectus.

The Investment Managers and/or the Sub-Investment Managers are responsible for managing the assets of the Underlying Fund in accordance with the investment parameters set out in the Articles and in this Singapore Prospectus and the relevant Investment Management Agreements and/or Sub-Investment Management Agreements. The Investment Managers and/or the Sub-Investment Managers may consult or seek advice from Investment Advisers from time to time for the relevant portfolios.

Past performance of the Investment Manager and Sub-Investment Managers is not necessarily indicative of their future performance or the Underlying Fund.

Please refer to the latest available Prospectus, including any Singapore prospectus, supplement, product highlight sheet or fund-specific appendix, where applicable, for further information on the Underlying Fund’s Manager. You may use the table of contents or index of the relevant document to locate the relevant disclosures.

3. Other Parties

The ILP Sub-Fund’s auditor is Ernst & Young LLP.

Please refer to the latest available Prospectus, including any Singapore prospectus, supplement, product highlight sheet or fund-specific appendix, where applicable, for further information on the Underlying Fund’s auditor and other parties. You may use the table of contents or index of the relevant document to locate the relevant disclosures.

4. Investment Objectives, Focus & Approach

The Underlying Fund aims to achieve income generation by investing at least 70% of its net assets in equity and equity-related securities (which are listed on any Regulated Market), fixed income and fixed income-related securities of companies and/or governments (which include agencies and supra-nationals in respect of fixed income and fixed income-related securities) located across the globe. The remaining assets of the Underlying Fund may be invested in cash and/or cash equivalents.

The Underlying Fund’s expected asset allocation range for each asset class is expected to be the following (as a percentage of the Underlying Fund’s net assets):

- Global equities and equity-related securities: 10-90%
- Global fixed Income and fixed income-related securities: 10-90%
- Cash and/or cash equivalents: 0-30%

The Underlying Fund may invest (up to 90% of its net assets) in higher-yielding debt securities rated below investment grade (i.e. below Baa3 by Moody’s or BBB- by Standard & Poor’s or Fitch) or unrated debt securities. The Underlying Fund may also invest up to 20% of its net assets in collateralized and/or securitized products, such as asset backed securities, mortgage backed securities and collateralised loan obligations.

5. ILP Sub-Fund Risks

Please refer to the latest available Prospectus, including any Singapore prospectus, supplement, product highlight sheet or fund-specific appendix, where applicable, for further information on the Underlying Fund's risks. You may use the table of contents or index of the relevant document to locate the relevant disclosures.

6. Fees and Charges

Please refer to the Product Summary.

7. Subscription/Redemption/Switching of Units

Please refer to the Product Summary.

8. Obtaining Prices of Units

Please refer to the Product Summary.

9. Suspension of Dealings

Please refer to the Product Summary and the latest available Prospectus, including any Singapore prospectus, supplement, product highlight sheet or fund-specific appendix, where applicable, for further information on the suspension of dealings. You may use the table of contents or index of the relevant document to locate the relevant disclosures.

10. Past Performance

NOTE: PAST PERFORMANCE IS NOT NECESSARILY INDICATIVE OF ITS FUTURE PERFORMANCE

Performance (%) as at 31 December 2024

Underlying Fund/Benchmark	1yr	3yrs (p.a)	5yrs (p.a)	10yrs (p.a)	Since Inception* (p.a)
Manulife GF - Global Multi-Asset Diversified Income Fund	3.67	-0.24	1.39	NA	2.21
Benchmark: NA	NA	NA	NA	NA	NA

*Refer to the Prospectus for the underlying fund's inception date.

The performance of the Underlying Fund is not measured against any benchmark as there is no suitable benchmark that reflects the investment strategy of the Underlying Fund.

Performance shown in SGD, unless otherwise stated, and calculated before sales charges are deducted. Fees and charges payable through deduction of premium or cancellation of units are excluded in deriving the performance. Performance is calculated on the assumption that all dividends and distributions are reinvested, taking into account all charges which would have been payable upon such reinvestment.

Source: Manulife Investment Management (Hong Kong) Limited, Bloomberg, Morningstar.

11. Expense Ratio & Turnover Ratio

As of 30 June 2024

Underlying Fund	Expense Ratio^	Turnover Ratio^
Manulife GF - Global Multi-Asset Diversified Income Fund	1.66%	27.66%

^The expense ratio is calculated in accordance with the requirements in the Investment Management Association of Singapore's guidelines on the disclosure of expense ratios (the "IMAS Guidelines") and is based on the Underlying Fund's latest audited accounts. The following expenses (where applicable) as set out in the IMAS Guidelines (as may be updated from time to time), are excluded from the calculation of the expense ratio:

- (a) brokerage and other transaction costs associated with the purchase and sales of investments (such as registrar charges and remittance fees);
- (b) foreign exchange gains and losses, whether realised or unrealised;
- (c) front-end loads, back-end loads and other costs arising on the purchase or sale of other funds;
- (d) tax deducted at source or arising on income received, including withholding tax;
- (e) interest expense; and
- (f) dividends and other distributions paid to the Holders.

^The turnover ratio is calculated based on the lesser of purchases or sales expressed as a percentage over daily average net asset value, over the same period used for calculating the expense ratio.

Source: Manulife Investment Management (Hong Kong) Limited, Bloomberg, Morningstar.

12. Soft Dollar Commissions or Arrangements

Etiqa Insurance Pte Ltd does not receive or enter into soft dollar commissions or arrangements in the management of the ILP Sub-Fund.

Please refer to the latest available Prospectus, including any Singapore prospectus, supplement, product highlight sheet or fund-specific appendix, where applicable, for further information on the soft dollar commissions or arrangements. You may use the table of contents or index of the relevant document to locate the relevant disclosures.

13. Conflicts of Interest

Etiqa Insurance Pte Ltd does not have any conflict of interest which may exist or arise in relation to the ILP Sub-Fund and its management.

Please refer to the latest available Prospectus, including any Singapore prospectus, supplement, product highlight sheet or fund-specific appendix, where applicable, for further information on the conflicts of interest. You may use the table of contents or index of the relevant document to locate the relevant disclosures.

14. Reports

The financial year end of the ILP Sub-Fund is 31 December. The semi-annual and annual report of the ILP Sub-Fund will be made available within two (2) months and three (3) months respectively, from the last date of the period to which reports relate to.

In addition, Etiqa Insurance Pte Ltd will make available financial reports of the underlying fund as they become available from the ILP Sub-Fund Manager. Policyholders can access these reports via the Etiqa Insurance Pte Ltd website at www.etiqa.com.sg.

15. Specialised ILP Sub-Fund

The ILP Sub-Fund is not a specialised fund as set out in the Code on Collective Investment Schemes issued by the Monetary Authority of Singapore.

16. Other Material Information

This Fund Summary should be read in conjunction with the relevant Product Summary, Product Highlights Sheet and Underlying Fund's Prospectus.

You understand that you will be provided with, and will read and understand the applicable sections of the most recent versions of the relevant Product Summary, Product Highlights Sheet and Underlying Fund's Prospectus in relation to the application for this Policy. The respective Product Summary, Product Highlights Sheet and Underlying Fund's Prospectus may also be found on the Etiqa Insurance Pte. Ltd. website at www.etiqa.com.sg.